ST2001 / Segue Therap - LARVOL DELTA

Adenosine AR/AR Antagonists Enabling Additional HR Antagonism for the Treatment of Parkinson's Disease. (PubMed, J Med Chem) - "Compound 4 (ST-2001, K (AR) = 11.5 nM, K (AR) = 7.25 nM) and 12 (ST-1992, K (AR) = 11.2 nM, K (AR) = 4.01 nM) were evaluated in vivo. l-DOPA-induced dyskinesia was improved after administration of compound 4 (1 mg kg, i.p. rats). Compound 12 (2 mg kg, p.o. mice) increased wakefulness representing novel pharmacological tools for PD therapy."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • Sleep Disorder